@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA45003 pubblicazioni:autoreCNRDi prodotto:ID168347 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS059 prodottidellaricerca:prodotto prodotto:ID168347 . @prefix modulo: . modulo:ID8529 prodottidellaricerca:prodotto prodotto:ID168347 . modulo:ID2664 prodottidellaricerca:prodotto prodotto:ID168347 . @prefix rdf: . @prefix retescientifica: . prodotto:ID168347 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID168347 rdfs:label "Tumor infiltration by Fc gamma RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID168347 pubblicazioni:anno "2010-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1002/ijc.25609"^^xsd:string . @prefix skos: . prodotto:ID168347 skos:altLabel "
Sconocchia G1,2; Zlobec I3; Lugli A3; Calabrese D3; Iezzi G2; Karamitopoulou E4; Patsouris ES5; Peros G6; Horcic M7; Tornillo L3; Zuber M8; Droeser R3; Muraro MG2; Mengus C2; Oertli D2; Ferrone S9,10,11; Terracciano L3; Spagnoli GC.2 (2010)
Tumor infiltration by Fc gamma RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma
in International journal of cancer (Print)
"^^rdf:HTML ; pubblicazioni:autori "Sconocchia G1,2; Zlobec I3; Lugli A3; Calabrese D3; Iezzi G2; Karamitopoulou E4; Patsouris ES5; Peros G6; Horcic M7; Tornillo L3; Zuber M8; Droeser R3; Muraro MG2; Mengus C2; Oertli D2; Ferrone S9,10,11; Terracciano L3; Spagnoli GC.2"^^xsd:string ; pubblicazioni:paginaInizio "2663"^^xsd:string ; pubblicazioni:paginaFine "2672"^^xsd:string ; pubblicazioni:altreInformazioni "2010 Aug 16. [Epub ahead of print] - PMID: 20715106"^^xsd:string ; pubblicazioni:numeroVolume "128"^^xsd:string . @prefix ns11: . prodotto:ID168347 pubblicazioni:rivista ns11:ID394711 ; pubblicazioni:numeroFascicolo "11"^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string ; pubblicazioni:affiliazioni "1 - Department of Medicine, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy;\n2 - Institute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland;\n3 - Institute of Pathology, University of Basel, Basel, Switzerland;\n4 - Second Department of Pathology, Medical school, University of Athens, Greece;\n5 - First Department of Pathology, Medical School, University of Athens, Greece;\n6 - Fourth Department of Surgery, Medical School, University of Athens, Greece;\n7 - Institute for Histological and Cytological Diagnostics, Aarau, Switzerland;\n8 - Department of Surgery, Kantonsspital, Olten, Switzerland;\n9 - Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;\n10 - Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;\n11 - Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA"^^xsd:string ; pubblicazioni:titolo "Tumor infiltration by Fc gamma RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma"^^xsd:string ; prodottidellaricerca:abstract "The prognostic significance of macrophage and natural killer (NK) cell infiltration in colorectal carcinoma (CRC) microenvironment is unclear. We investigated the CRC innate inflammatory infiltrate in over 1,600 CRC using two independent tissue microarrays and immunohistochemistry. Survival time was assessed using the Kaplan-Meier method and Cox proportional hazards regression analysis in a multivariable setting. Spearman's rank correlation tested the association between macrophage and lymphocyte infiltration. The Basel study included over 1,400 CRCs. The level of CD16+ cell infiltration correlated with that of CD3+ and CD8+ lymphocytes but not with NK cell infiltration. Patients with high CD16+ cell infiltration (score 2) survived longer than patients with low (score 1) infiltration (p = 0.008), while no survival difference between patients with score 1 or 2 for CD56+ (p = 0.264) or CD57+ cell (p = 0.583) infiltration was detected. CD16+ infiltrate was associated with improved survival even after adjusting for known prognostic factors including pT, pN, grade, vascular invasion, tumor growth and age [(p = 0.001: HR (95% CI) = 0.71 (0.6-0.9)]. These effects were independent from CD8+ lymphocyte infiltration [(p = 0.036: HR (95% CI) = 0.81 (0.7-0.9)] and presence of metastases [(p = 0.002: HR (95% CI) = 0.43 (0.3-0.7)]. Phenotypic studies identified CD16+ as CD45+CD33+CD11b+CD11c+ but CD64- HLA-DR-myeloid cells. Beneficial effects of CD16+ cell infiltration were independently validated by a study carried out at the University of Athens confirming that patients with CD16 score 2 survived longer than patients with score 1 CRCs (p = 0.011). Thus, CD16+ cell infiltration represents a novel favorable prognostic factor in CRC."@en ; prodottidellaricerca:prodottoDi istituto:CDS059 , modulo:ID2664 , modulo:ID8529 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA45003 . @prefix parolechiave: . prodotto:ID168347 parolechiave:insiemeDiParoleChiave . ns11:ID394711 pubblicazioni:rivistaDi prodotto:ID168347 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID168347 .